Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HASPIN | Q8TF76 | 9/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609606 | 0.81 | HASPIN (0.56) | HASPINGSK3BALDH1A1DAPK3PLK1 | |
| SCHEMBL2502319 | 0.80 | HASPIN (0.54) | TSHRHASPINGSK3BALDH1A1DAPK3 | |
| SCHEMBL30481290 | 0.80 | HASPIN (0.54) | TSHRHASPINGSK3BDAPK3PLK1 | |
| SCHEMBL568019 | 0.80 | HASPIN (0.54) | TSHRHASPINGSK3BDAPK3PLK1 | |
| SCHEMBL18935881 | 0.80 | HASPIN (0.54) | HASPINGSK3BDAPK3PLK1PLK3 | |
| SCHEMBL14423247 | 0.80 | HASPIN (0.54) | TSHRHASPINGSK3BDAPK3PLK1 | |
| SCHEMBL3589139 | 0.80 | HASPIN (0.54) | TSHRHASPINGSK3BDAPK3PLK1 | |
| SCHEMBL8856387 | 0.80 | HASPIN (0.55) | TSHRHASPINGSK3BDAPK3PLK1 | |
| Bromide SCHEMBL16238937 | 0.79 | HASPIN (0.52) | HASPINGSK3BDAPK3PLK1PLK3 | |
| SCHEMBL31165768 | 0.78 | HASPIN (0.49) | TSHRHASPINGSK3BDAPK3PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363424-B1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| US-20250051351-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-11999749-B2 | Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto | GENENTECH, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4363424-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | Genentech, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117580840-A | Synthesis of bis-mesylate salt of 4-amino-N- (1- ((3-chloro-2-fluorophenyl) amino) -6-methylisoquinolin-5-yl) thieno [3,2-D ] pyrimidine-7-carboxamide and intermediates thereof | 基因泰克公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023278981-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-113387823-B | Anthranilic acid and derivative thereof, and synthetic method and application thereof | 华东师范大学 | 2022-07-08 | — | — | CN | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1976836-A2 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-5880135-A | ANTAGONIST ACTIVITY WITH RESPECT TO CORTICOTROPIN RELEASING HORMONE | SANOFI (FR) | 1999-03-09 | — | — | US | disclosed |
| CN-1188476-A | 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions thereof | SANOFI SA (FR) | 1998-07-22 | — | — | CN | disclosed |
| EP-0833822-A1 | 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000868-A1 | 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | TSHR 1037/4885HASPIN 1355/4885GSK3B 229/4885 |
| US-20250051351-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | BRAF, RAF1, KRAS | TSHR 1196/4885HASPIN 2597/4885GSK3B 830/4885 |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | BRAF, RAF1, KRAS | TSHR 1190/4885HASPIN 2342/4885GSK3B 692/4885 |
| US-11999749-B2 | Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto | BRAF, RAF1, KRAS | TSHR 1201/4885HASPIN 2625/4885GSK3B 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.